

Financial news for PTCT dated on 2020-05-07: PTC Therapeutics Files Prospectus Relates To Resales Of 2.8M Shares Of Its Common Stock By Selling Shareholders

Financial news for PTCT dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for PTCT dated on 2020-05-06: PTC Therapeutics To Acquire Censa Pharmaceuticals For \$10M Upfront And Up To 850K Shares Of PTC Common Stock

Financial news for PTCT dated on 2020-05-06: PTC Therapeutics to Acquire Censa Pharmaceuticals; PTC Will Pay An Upfront Consideration Of Approximately \$10M In Cash And Up To 850K Shares Of PTC Common Stock

Financial news for PTCT dated on 2020-05-01: SunTrust Robinson Humphrey Maintains Buy on PTC Therapeutics, Lowers Price Target to \$75

Financial news for PTCT dated on 2020-04-30: PTC Therapeutics Q1 EPS \$(1.810) Misses \$(1.310) Estimate, Sales \$68.259M Miss \$81.940M Estimate

Financial news for PTCT dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for PTCT dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for PTCT dated on 2020-04-28: PTC Therapeutics Announced Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy

Financial news for PTCT dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for PTCT dated on 2020-04-09: Citigroup Upgrades PTC Therapeutics to Buy

Financial news for PTCT dated on 2020-04-08: Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Lowers Price Target to \$85

Financial news for PTCT dated on 2020-04-07: PTC Therapeutics Reports FDA Extended PDUFA Date For Its Review Of Risdiplam New Drug Application To Aug. 24, 2020

Financial news for PTCT dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for PTCT dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for PTCT dated on 2020-03-03: Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Raises Price Target to \$86

Financial news for PTCT dated on 2020-03-02: PTC Therapeutics Q4 Sales \$96.459M Beat \$95.24M Estimate

Financial news for PTCT dated on 2020-02-29: The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

Financial news for PTCT dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for PTCT dated on 2020-02-20: RBC Capital Downgrades PTC Therapeutics to Sector Perform, Lowers Price Target to \$60

Financial news for PTCT dated on 2020-02-20: Citigroup Downgrades PTC Therapeutics to Neutral, Raises Price Target to \$71

Financial news for PTCT dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for PTCT dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for PTCT dated on 2020-02-12: Stocks That Hit 52-Week Highs On Wednesday

Financial news for PTCT dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies

Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for PTCT dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for PTCT dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for PTCT dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for PTCT dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for PTCT dated on 2020-02-05: Stocks That Hit 52-Week Highs On Wednesday

Financial news for PTCT dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for PTCT dated on 2020-02-03: PTC Therapeutics Highlights First Publication Of Data Showing Translarna 'Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy'

Financial news for PTCT dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for PTCT dated on 2020-01-23: UPDATE: Cantor Fitzgerald On PTC Therapeutics Is 'confident in a May approval or earlier based on the data generated between FIREFISH and SUNFISH, and we think that an oral medicine is a game changer in this population taking intrathecal injections'

Financial news for PTCT dated on 2020-01-23: UPDATE: Cantor Fitzgerald Maintains Overweight On PTC Therapeutics, Raises Target To \$81 As Firm Notes 'Risdiplam will be a blockbuster' Adjusts 'PoS for risdiplam to 100% from 75% and factored in the milestones in the coming years'

Financial news for PTCT dated on 2020-01-23: Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to \$81

Financial news for PTCT dated on 2020-01-23: Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy

Financial news for PTCT dated on 2020-01-22: The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

Financial news for PTCT dated on 2020-01-21: Stocks That Hit 52-Week Highs On Tuesday

Financial news for PTCT dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for PTCT dated on 2020-01-13: PTC Therapeutics Sees 2020 Duchenne Franchise Revenue \$320M-\$340M, Provides Corporate Update

Financial news for PTCT dated on 2020-01-10: The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

Financial news for PTCT dated on 2020-01-09: Stocks That Hit 52-Week Highs On Thursday

Financial news for PTCT dated on 2020-01-09: The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

Financial news for PTCT dated on 2020-01-08: The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results

Financial news for PTCT dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for PTCT dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for PTCT dated on 2019-12-05: Stocks That Hit 52-Week Highs On Thursday

Financial news for PTCT dated on 2019-12-04: The Daily Biotech Pulse: Roche's

Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

Financial news for PTCT dated on 2019-12-03: Stocks That Hit 52-Week Highs On Tuesday

Financial news for PTCT dated on 2019-11-25: PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy

Financial news for PTCT dated on 2019-11-13: Credit Suisse Maintains Outperform on PTC Therapeutics, Raises Price Target to \$58

Financial news for PTCT dated on 2019-11-12: Benzinga's Top Upgrades, Downgrades For November 12, 2019

Financial news for PTCT dated on 2019-11-12: SunTrust Robinson Humphrey Initiates Coverage On PTC Therapeutics with Buy Rating, Announces \$78 Price Target

Financial news for PTCT dated on 2019-11-11: 20 Stocks Moving in Monday's Pre-Market Session

Financial news for PTCT dated on 2019-11-11: PTC Therapeutics Announces Risdiplam Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy

Financial news for PTCT dated on 2019-10-30: Citigroup Maintains Buy on PTC Therapeutics, Lowers Price Target to \$55

Financial news for PTCT dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for PTCT dated on 2019-10-29: PTC Therapeutics Q3 EPS \$(1.06) Misses \$(0.76) Estimate, Sales \$71.4M Miss \$73.02M Estimate

Financial news for PTCT dated on 2019-10-24: PTC Therapeutics Offers Results From Long-Term AADC Deficiency Gene Therapy Treatment Showing Sustained Improvements

Financial news for PTCT dated on 2019-10-04: PTC Therapeutics Highlights Analysis Showing Translarna(tm) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy

Financial news for PTCT dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for PTCT dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for PTCT dated on 2019-09-19: 52 Biggest Movers From Yesterday

Financial news for PTCT dated on 2019-09-18: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PTCT dated on 2019-09-18: PTC Therapeutics Prices ~2.475M Share Common Stock Offering At \$40.40/Share

Financial news for PTCT dated on 2019-09-18: PTC Therapeutics shares are trading lower after the company reported a \$100 million common stock offering.

Financial news for PTCT dated on 2019-09-18: 10 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for PTCT dated on 2019-09-18: 30 Stocks Moving in Wednesday's Pre-Market Session

Financial news for PTCT dated on 2019-09-18: The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

Financial news for PTCT dated on 2019-09-17: PTC Therapeutics shares are trading lower after the company reported a \$100 million common stock offering.

Financial news for PTCT dated on 2019-09-17: PTC Therapeutics Reports \$100M Common Stock Offering

Financial news for PTCT dated on 2019-08-06: PTC Therapeutics Q2 EPS \$(0.75) Misses \$(0.58) Estimate, Sales \$85.522M Beat \$78.64M Estimate

Financial news for PTCT dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for PTCT dated on 2019-07-29: 40 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for PTCT dated on 2019-07-08: PTC Therapeutics Option Alert: Dec 20 \$50 Calls at the Ask: 4000 @ \$4.1 vs 9 OI; Earnings 8/6 After Close [est] Ref=\$44.04

Financial news for PTCT dated on 2019-07-01: PTC Therapeutics Announces Gene Therapy Licensing Agreement with Odylia Therapeutics, Terms Not Disclosed

Financial news for PTCT dated on 2019-06-28: 28 Stocks Moving In Friday's Pre-Market Session

Financial news for PTCT dated on 2019-06-28: UPDATE: PTC Says Plans To Request Reexamination Of Procedure Within Next 2 Weeks, Sees New Examination Lasting ~4 Months

Financial news for PTCT dated on 2019-06-28: PTC Therapeutics Reports Negative EMA's CHMP Completed Review Of Proposed Indication Extension For Translarna; Co. Was Informed EMA Reps That EPAR Will Be Updated To Clarify Patients Who Start Translarna Not Required To Discontinue Treatment

Financial news for PTCT dated on 2019-06-07: PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients

Financial news for PTCT dated on 2019-06-07: PTC Therapeutics Reports FDA Approval For Expansion of the EMFLAZA(r) (deflazacort) Labeling to Include Patients 2-5 Years of Age

Financial news for PTCT dated on 2019-05-20: PTC Therapeutics Shares Tick Lower Here As Traders Circulate Word RBC Capital Out Positive On Stock, CitedA ClinicalTrials.gov Record For Co.'s AVXS-101

Financial news for PTCT dated on 2019-05-13: 10 Biggest Price Target Changes For Monday

Financial news for PTCT dated on 2019-05-13: Bank of America Upgrades PTC Therapeutics, Inc. - Common Stock to Buy, Raises Price Target to \$49

Financial news for PTCT dated on 2019-05-09: PTC Therapeutics Announces \$4M Investment in MRI Interventions

Financial news for PTCT dated on 2019-05-07: The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

Financial news for PTCT dated on 2019-05-04: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for PTCT dated on 2019-05-02: PTC Therapeutics Q1 EPS \$(1.29) Misses \$(0.73) Estimate, Sales \$53.6M Miss \$70.01M Estimate

Financial news for PTCT dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for PTCT dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for PTCT dated on 2019-04-11: Benzinga's Top Upgrades, Downgrades For April 11, 2019

Financial news for PTCT dated on 2019-04-11: Bernstein Initiates Coverage On PTC Therapeutics with Outperform Rating, Announces \$48 Price Target

Financial news for PTCT dated on 2019-04-10: Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds

Financial news for PTCT dated on 2019-02-28: PTC Therapeutics Sees FY19 Net Product Revenues \$285M-\$305M, Sees Adj. R&D And SG&A Expense \$360M-\$370M

Financial news for PTCT dated on 2019-02-28: PTC Therapeutics Q4 EPS \$(0.96) Misses \$(0.33) Estimate, Sales \$86.34M Beat \$84.61M Estimate

Financial news for PTCT dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for PTCT dated on 2019-02-25: Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Financial news for PTCT dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for PTCT dated on 2019-01-24: 54 Biggest Movers From Yesterday

Financial news for PTCT dated on 2019-01-23: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PTCT dated on 2019-01-23: PTC Therapeutics shares are trading lower after the company announced a 6.72 share common stock offering at \$30.20 per share.

Financial news for PTCT dated on 2019-01-23: PTC Therapeutics Prices 6.72M Share Common Stock Offering At \$30.20/Share

Financial news for PTCT dated on 2019-01-23: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PTCT dated on 2019-01-23: The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study

Financial news for PTCT dated on 2019-01-22: PTC Therapeutics Reports \$200M Common Stock Offering

Financial news for PTCT dated on 2019-01-07: PTC Therapeutics Sees FY19 Sales \$285M-\$305M May Not Compare To \$348.9M Est.

Financial news for PTCT dated on 2019-01-07: PTC Therapeutics Provides Corporate Update And Outlines 5-year Strategic Plan At 2019 J.P. Morgan Healthcare Conference

Financial news for PTCT dated on 2018-11-06: The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

Financial news for PTCT dated on 2018-11-05: PTC Narrows FY18 Product Sales Guidance From \$260M-\$295M To \$260M-\$280M

Financial news for PTCT dated on 2018-11-05: PTC Therapeutics Q3 EPS \$(1.06) Misses \$(0.40) Estimate, Sales \$53.591M Miss \$70.9M Estimate

Financial news for PTCT dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for PTCT dated on 2018-10-07: PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation

Financial news for PTCT dated on 2018-10-03: PTC Therapeutics Shares Spike Over \$46 Level To Session High As Hearing BofA Upgraded Stock Midday; Shares Up 3.9% For Session

Financial news for PTCT dated on 2018-10-03: Traders Circulate Comment From JP Morgan On PTC Therapeutics: 'Solid Updates for Risdi at WMS. Near-term Buying Opp'y on Unfounded Weakness'; PTC Shares Down 3% For Session, But Up ~16% From Session Low Just After Open

Financial news for PTCT dated on 2018-10-03: Risdiplam Demonstrates Preliminary Evidence Of Clinical Benefit In Type 1, 2, & 3 Spinal Muscular Atrophy Patients; Patients Showed Increase In Survival And Increase In Motor Function

Financial news for PTCT dated on 2018-10-01: Cantor Fitzgerald Initiates Coverage On PTC Therapeutics with Overweight Rating, Announces \$66 Price Target

Financial news for PTCT dated on 2018-09-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for PTCT dated on 2018-09-26: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for PTCT dated on 2018-08-24: The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict

Financial news for PTCT dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for PTCT dated on 2018-08-07: PTC Therapeutics Reaffirms FY18 Sales Guidance \$260M-\$295M vs \$271.8M Estimate

Financial news for PTCT dated on 2018-08-07: PTC Therapeutics, Inc. - Common Stock Q2 EPS \$(0.21) Beats \$(0.30) Estimate, Sales \$68.743M Beat \$65.7M Estimate

Financial news for PTCT dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for PTCT dated on 2018-08-02: Akcea Therapeutics, PTC Therapeutics Partner to Commercialize Two Rare Disease Drugs in Latin America; PTC To Gain Exclusive Rights To TEGSEDI and WAYLIVRA In These Areas And Akcea To Receive Licensing Fee Of \$18M

Financial news for PTCT dated on 2018-07-24: PTC Therapeutics Reports Publication of Data Demonstrating the Clinical Differentiated Benefit of Deflazacort, Says delazacort Had Notably Less Decline From Baseline In 6-Minute Walk Distance At Week 48 vs Those Treated With prednisone/prednisolone

Financial news for PTCT dated on 2018-07-24: Citigroup Maintains Buy on PTC Therapeutics, Raises Price Target to \$50

Financial news for PTCT dated on 2018-07-23: 41 Biggest Movers From Friday

Financial news for PTCT dated on 2018-07-20: 31 Stocks Moving In Friday's Mid-Day Session

Financial news for PTCT dated on 2018-07-20: Mid-Morning Market Update: Markets Mostly Flat; Honeywell Tops Q2 Expectations

Financial news for PTCT dated on 2018-07-20: 32 Stocks Moving In Friday's Pre-Market Session

Financial news for PTCT dated on 2018-07-20: Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2

Financial news for PTCT dated on 2018-07-20: 10 Stocks To Watch For July 20, 2018

Financial news for PTCT dated on 2018-07-19: 6 Stocks Moving In Thursday's After-Hours Session

Financial news for PTCT dated on 2018-07-19: PTC Therapeutics Shares Resume Trade, Now Up 6.5%

Financial news for PTCT dated on 2018-07-19: PTC Therapeutics Shares To Resume At 4:40 p.m. EDT

Financial news for PTCT dated on 2018-07-19: PTC Therapeutics To Acquire Agilis Biotherapeutics For \$50M Cash and \$150M In Common Stock With Potential Future \$60M In Milestone Payments, With An Add'l \$535M In Regulatory Approval Milestone Payments and \$150M In Tiered Commercial Milestones of \$150M

Financial news for PTCT dated on 2018-07-19: PTC Therapeutics Shares Halted News Pending

Financial news for PTCT dated on 2018-07-19: Benzinga's Top Upgrades, Downgrades For July 19, 2018

Financial news for PTCT dated on 2018-07-19: Credit Suisse Initiates Coverage On PTC Therapeutics with Outperform Rating, Announces \$49 Price Target

Financial news for PTCT dated on 2018-07-09: PTC Therapeutics Reports Data from its Translarna Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy

Financial news for PTCT dated on 2018-06-20: Benzinga's Top Upgrades, Downgrades For June 20, 2018

Financial news for PTCT dated on 2018-06-20: The Market In 5 Minutes: Walgreens To Replace GE In The Dow Jones Industrial Average

Financial news for PTCT dated on 2018-06-20: Barclays Upgrades PTC Therapeutics to Equal-Weight

Financial news for PTCT dated on 2018-06-20: 48 Biggest Movers From Yesterday

Financial news for PTCT dated on 2018-06-19: Mid-Afternoon Market Update: Crude Oil Down 1.5%; Sarepta Shares Spike Higher

Financial news for PTCT dated on 2018-06-19: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PTCT dated on 2018-06-19: Mid-Day Market Update: Dow Down 350 Points; Tellurian Shares Plunge

Financial news for PTCT dated on 2018-06-19: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Tues., Jun. 19, 2018

Financial news for PTCT dated on 2018-06-19: Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares

Financial news for PTCT dated on 2018-06-19: 60 Biggest Movers From Yesterday

Financial news for PTCT dated on 2018-06-18: William Blair Upgrades PTC Therapeutics On Risdiplam Prospects

Financial news for PTCT dated on 2018-06-18: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for PTCT dated on 2018-06-18: PTC Therapeutics Option Alert: Sep 21 \$50 Calls Sweep (2) near the midpoint: 1439 @ \$4.0 vs 0 OI; Earnings 8/7 After Close [est] Ref=\$48.234

Financial news for PTCT dated on 2018-06-18: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning Of Mon., Jun. 18, 2018

Financial news for PTCT dated on 2018-06-18: Mid-Morning Market Update: Markets Open Lower; Vintage Capital To Acquire Rent-A-Center For \$15/Share

Financial news for PTCT dated on 2018-06-18: Benzinga Pro's 5 Stocks To Watch Today

Financial news for PTCT dated on 2018-06-18: Benzinga's Top Upgrades, Downgrades For June 18, 2018

Financial news for PTCT dated on 2018-06-18: The Market In 5 Minutes: China, OPEC, Banks, Bitcoin And More

Financial news for PTCT dated on 2018-06-18: PTC Therapeutics Shares Up 37.2% Premarket After Co. On Saturday Reported Positive Risdiplam (RG7916) In Babies With Type 1 Spinal Muscular Atrophy

Financial news for PTCT dated on 2018-06-18: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for PTCT dated on 2018-06-18: William Blair Upgrades PTC Therapeutics to Outperform

Financial news for PTCT dated on 2018-06-18: RBC Capital Upgrades PTC Therapeutics to Outperform

Financial news for PTCT dated on 2018-06-16: PTC Therapeutics Announces Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CuresMA Conference

Financial news for PTCT dated on 2018-06-12: Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate

Financial news for PTCT dated on 2018-06-01: Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

Financial news for PTCT dated on 2018-06-01: PTC Therapeutics Reports CHMP Adopted Positive Opinion For Expansion Of Translarna Label To Include Patients As Young As 2 Years Of Age

Financial news for PTCT dated on 2018-05-09: PTC Therapeutics Q1 EPS \$(0.46) Misses \$(0.28) Estimate, Sales \$56.062M Miss \$64.75M Estimate

Financial news for PTCT dated on 2018-05-09: Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Financial news for PTCT dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for PTCT dated on 2018-04-24: PTC Therapeutic Announces Preliminary Clinical Data from FIREFISH Trial in Type 1 SMA Patients Presented at #AAN2018

Financial news for PTCT dated on 2018-04-04: Benzinga's Top Upgrades, Downgrades For April 4, 2018

Financial news for PTCT dated on 2018-04-04: The Market In 5 Minutes: China Tariffs, Zuckerberg, Spotify, Model 3 Deliveries And More

Financial news for PTCT dated on 2018-04-04: PTC Therapeutics, CHDI Foundation Announce a Partnership on a Small-Molecule Therapeutic for Huntington's Disease

Financial news for PTCT dated on 2018-04-04: Barclays Downgrades PTC Therapeutics to Underweight

Financial news for PTCT dated on 2018-03-29: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for PTCT dated on 2018-03-29: 40 Biggest Movers From Yesterday

Financial news for PTCT dated on 2018-03-29: PTC Therapeutics Prices 4M Share Public Offering of Common Stock @\$27.04/Share

Financial news for PTCT dated on 2018-03-28: 32 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PTCT dated on 2018-03-28: PTC Therapeutics Shares Down 12.9% After Co. Tuesday Announced 4M Share Common Stock Offering

Financial news for PTCT dated on 2018-03-27: PTC Therapeutics Announces 4M Share Common Stock Offering

Financial news for PTCT dated on 2018-03-08: 41 Biggest Movers From Yesterday

Financial news for PTCT dated on 2018-03-07: 31 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PTCT dated on 2018-03-06: PTC Therapeutics Sees FY18 Net Product Sales \$260M-\$295M

Financial news for PTCT dated on 2018-03-06: PTC Therapeutics Reports Q4 EPS \$0.03 vs \$(0.78) In Same Qtr. Last Year, Sales \$78.03M vs \$74.4M Est.

Financial news for PTCT dated on 2018-03-06: PTC Therapeutics Q4 Earnings Preview

Financial news for PTCT dated on 2018-03-02: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for PTCT dated on 2018-02-20: FDA Reiterates Its Prior Decision On PTC's Appeal Of The CRL In Relation To The New Drug Application For ataluren

Financial news for PTCT dated on 2018-02-13: PTC Therapeutics Reports Launch Of 4th Annual STRIVE Grant Award Program For DMD

Financial news for PTCT dated on 2018-01-08: PTC Therapeutics Sees FY18 Net Product Sales \$260M-\$295M vs \$217.5M Est.

Financial news for PTCT dated on 2018-01-08: PTC Therapeutics Sees FY17 Sales ~\$195M vs \$181.5M Est.

Financial news for PTCT dated on 2017-11-16: The Market In 5 Minutes: Low Floats, Ron Johnson, And Jobless Claims

Financial news for PTCT dated on 2017-11-16: JP Morgan Upgrades PTC Therapeutics to Neutral

Financial news for PTCT dated on 2017-11-02: PTC Therapeutics Sees FY17 Translarna Sales \$120M-\$140M, EMFLAZA Sales From \$15M-\$20M to \$20M-\$25M, Total Sales From \$155M-\$180M to \$160M-\$185M vs \$173.38M Est.

Financial news for PTCT dated on 2017-11-02: PTC Therapeutics Reports Q3 EPS \$(0.82) vs \$(0.60) Est., Sales \$41.853M vs \$45.03M Est.

Financial news for PTCT dated on 2017-10-26: Bank of America Downgrades PTC Therapeutics to Underperform

Financial news for PTCT dated on 2017-10-26: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for PTCT dated on 2017-10-25: PTC Therapeutics Shares Now Up 5% Following Resumption Of Trade

Financial news for PTCT dated on 2017-10-25: PTC Therapeutics Shares Resume Trade, Now Up ~2%

Financial news for PTCT dated on 2017-10-25: PTC Therapeutics To Open 12:35 p.m.

Financial news for PTCT dated on 2017-10-25: PTC Therapeutics Receives Complete Response Letter For Ataluren's NDA

Financial news for PTCT dated on 2017-10-25: PTC Therapeutics Halted Pending News

Financial news for PTCT dated on 2017-10-24: Benzinga's Option Alert Recap From October 24

Financial news for PTCT dated on 2017-10-24: PTC Therapeutics Option Alert: Nov 17 \$20 Calls Sweep (17) at the Ask: 850 @ \$0.5 vs 2800 OI; Ref=\$16.35

Financial news for PTCT dated on 2017-10-24: REMINDER: PTC Therapeutics Has PDUFA Date For Ataluren Today

Financial news for PTCT dated on 2017-10-23: PTC Therapeutics Shares Fall ~\$0.30 From Recent Highs As Traders Circulate Article From Regional Paper Highlighting 1 Man's Struggle With MS; Includes 'According to PTC, the FDA will notify the company by Tuesday whether or not ataluren has been approved'

Financial news for PTCT dated on 2017-10-23: PTC Therapeutics Shares Spike ~\$0.10, Now Paring Gains And Largely Unaffected; Traders Circulating New Haven Register Article 'Man awaits FDA decision on drug that treats muscular dystrophy'

Financial news for PTCT dated on 2017-10-12: PTC Therapeutics Reports Conclusion Of Dose-Finding Part OF SUNFISH Study, Triggers \$20M Payment From Roche To Co.

Financial news for PTCT dated on 2017-10-09: Is The Likelihood Of An FDA Complete Response Letter Fully Priced In To PTC Therapeutics?

Financial news for PTCT dated on 2017-10-09: 18 Biggest Mid-Day Losers For Monday

Financial news for PTCT dated on 2017-10-09: Mid-Morning Market Update: Markets Mostly Flat; Axalta Lowers 2017 Forecast

Financial news for PTCT dated on 2017-10-09: Benzinga's Top Upgrades, Downgrades For October 9, 2017

Financial news for PTCT dated on 2017-10-09: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for PTCT dated on 2017-10-09: JP Morgan Downgrades PTC Therapeutics to Underweight

Financial news for PTCT dated on 2017-10-03: PTC Reports RG7916 Increased SMN Protein Production in SUNFISH Clinical Trial in Patients with Type 2/3 Spinal Muscular Atrophy

Financial news for PTCT dated on 2017-10-02: Watch These 7 Huge Call Purchases In Monday Trade

Financial news for PTCT dated on 2017-09-29: Benzinga's Option Alert Recap From September 29

Financial news for PTCT dated on 2017-09-29: U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'

Financial news for PTCT dated on 2017-09-29: 18 Biggest Mid-Day Gainers For Friday

Financial news for PTCT dated on 2017-09-29: PTC Therapeutics Option Alert: Dec 15 \$30 Calls Sweep (4) at the Ask: 800 @ \$0.5 vs 23 OI; Ref=\$19.88

Financial news for PTCT dated on 2017-09-29: 16 Stocks Moving In Friday's Pre-Market Session

Financial news for PTCT dated on 2017-09-28: PTC Shares Rebounding From After-Hour Lows; Stock Down ~1.2%

Financial news for PTCT dated on 2017-09-28: PTC Therapeutics Shares Resume, Down ~12.4%

Financial news for PTCT dated on 2017-09-28: PTC Shares To Resume Trade At 5:50 p.m. EDT

Financial news for PTCT dated on 2017-09-28: Recent 8-K From PTC Showed 10 Members Of AdCom Panel Voted Translarna Could Be Effective, But Data Are Inconclusive, And More Week Would Be Needed...To Establish [Effectiveness]; 1 Member Voted 'Data Are Sufficient To Conclude [Translarna] Is Effective'

Financial news for PTCT dated on 2017-09-28: FDA AdCom Panel Says PTC's DMD Treatment 'May Work' But Data Is Inconclusive, More Work Needed To Be Done

Financial news for PTCT dated on 2017-09-28: Attention Biotech Investors, Here's Your PDUFA Primer For October

Financial news for PTCT dated on 2017-09-28: UPDATE: PTC Therapeutics Shares Halted Ahead Of FDA AdCom Panel Meeting For Translarna

Financial news for PTCT dated on 2017-09-28: PTC Therapeutics Shares Halted News Pending

Financial news for PTCT dated on 2017-09-26: 15 Biggest Mid-Day Losers For Tuesday

Financial news for PTCT dated on 2017-09-26: Credit Suisse Weighs In Ahead Of PTC Therapeutics' Thursday AdCom Panel For Translarna

Financial news for PTCT dated on 2017-09-26: PTC Therapeutics Shares At New Session Low, Down 24%

Financial news for PTCT dated on 2017-09-26: STAT News Adam Feuerstein Publishes 'FDA rips into PTC's Duchenne muscular dystrophy drug as advisory panel looms'

Financial news for PTCT dated on 2017-09-26: Adam Feuerstein Tweets: The FDA's briefing document on \$PTCT Translarna is wonderfully transparent, offers great behind-scenes look at regulatory process.

Financial news for PTCT dated on 2017-09-26: UPDATE: PTC Therapeutics AdCom Panel Briefing Doc Shows 'more work would be needed to establish whether ataluren is effective'

Financial news for PTCT dated on 2017-09-26: PTC Therapeutics Shares Down 15% In Pre-Market Action, Up ~\$1.60 From \$15 Low; AdCom Panel Briefing Docs Made Available Today; Panel Meeting Is Thursday, Sept. 28

Financial news for PTCT dated on 2017-09-22: Seeing Profit Taking In PTC Therapeutics Shares Fri., Down 6% As \$20 Support Level Fails To Hold; Stock Has Rallied 120% Since End Of May

Financial news for PTCT dated on 2017-08-23: William Blair Initiates Coverage On PTC Therapeutics with Market Perform Rating

Financial news for PTCT dated on 2017-08-08: PTC Therapeutics Reports Q2 Loss/Share \$(0.44) vs. \$(1.48) Est., Sales \$47.96M vs. \$28.78M Est.

Financial news for PTCT dated on 2017-08-01: Adam Feuerstein Tweets: Is the FDA telegraphing a rejection for \$PTCT DMD drug? --> statnews.com/2017/08/01/ptc...

Financial news for PTCT dated on 2017-07-26: Lightning Round: Jim Cramer Advises His Viewers On Hertz, Macy's And More

Financial news for PTCT dated on 2017-07-19: Benzinga's Option Alert Recap From July 19

Financial news for PTCT dated on 2017-07-19: PTC Therapeutics Option Alert: Aug 18 \$20 Calls Above Ask!: 500 @ \$1.611 vs 46 OI; Ref=\$19.57

Financial news for PTCT dated on 2017-06-06: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for PTCT dated on 2017-06-06: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PTCT dated on 2017-06-06: PTC Therapeutics Reports FDA Panel Meeting for Ataluren for Treatment of Nonsense Mutation Dystrophinopathy on Oct. 24, 2017

Financial news for PTCT dated on 2017-06-06: Watch These 8 Huge Call Purchases In Tuesday Trade

Financial news for PTCT dated on 2017-06-05: Option Alert: PTC Therapeutics Dec17 18.0 Calls: 2500 @ ASK \$2.00: 2500 traded vs 277 OI: Earnings 8/3 Before Open (est) \$13.12 Ref

Financial news for PTCT dated on 2017-06-05: PTC Therapeutics Names Marcio Souza COO

Financial news for PTCT dated on 2017-06-01: PTC Therapeutics Moves On Old Report

Financial news for PTCT dated on 2017-06-01: PTC Therapeutics Spokesperson Tells

Benzinga 'This is Very Old News...Phase 3 was Completed Almost Two Years Ago'

Financial news for PTCT dated on 2017-06-01: PTC Study Of Ataluren Has Been Terminated

Financial news for PTCT dated on 2017-05-08: PTC Therapeutics Reports Q1 Sales \$26.54M vs \$28.6M Est., EPS \$(0.85) vs \$(1.03) Est.

Financial news for PTCT dated on 2017-04-10: PTC Therapeutics CFO Shane Kovacs To Leave Company

Financial news for PTCT dated on 2017-03-30: PTC Therapeutics Pops to High of \$9.11 on Volume

Financial news for PTCT dated on 2017-03-24: Adam Feuerstein Tweets: \$PTCT withdrew the EMA application for Translarna in cystic fibrosis.
ema.europa.eu/ema/pages/incl...

Financial news for PTCT dated on 2017-03-22: PTC Therapeutics Shares Dip ~\$0.17 Over Last Min as Traders Circulating Press Release from Oversight & Gov't Reform 'Sanders and Cummings Request Pricing Info From PTC Therapeutics for Critical Drug'

Financial news for PTCT dated on 2017-03-17: Wall Street's M&A Chatter From March 17: Wynn, Innocoll, PTC Therapeutics

Financial news for PTCT dated on 2017-03-16: Adam Feuerstein Tweets: \$PTCT plans to "reexamine" Emflaza price.

Financial news for PTCT dated on 2017-03-16: PTCT To Acquire Emflaza From Marathon For \$140M Compromising Of Cash And Stock

Financial news for PTCT dated on 2017-03-16: PTC Sees FY17 Ex-US Translarna Net Sales \$105M-\$125M

Financial news for PTCT dated on 2017-03-16: PTC Therapeutics Reports Q4 Loss \$26.8M vs \$50.9M in Same Qtr. Last Year, Sales \$25.2M

Financial news for PTCT dated on 2017-03-16: PTC Therapeutics to Buy Emflaza for Treatment of DMD in US from Marathon Pharma for Upfront Consideration of \$140M, Single Sales-Based Milestone of \$50M

Financial news for PTCT dated on 2017-03-16: Earnings Scheduled For March 16, 2017

Financial news for PTCT dated on 2017-03-14: Earnings Scheduled For March 14, 2017

Financial news for PTCT dated on 2017-03-06: 15 Biggest Mid-Day Gainers For Monday

Financial news for PTCT dated on 2017-03-06: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for PTCT dated on 2017-03-06: PTC Therapeutics Reports FDA Acknowledgment of NDA Filing for Translarna

Financial news for PTCT dated on 2017-03-03: 8 Biggest Price Target Changes For Friday

Financial news for PTCT dated on 2017-03-03: Benzinga's Top Upgrades, Downgrades For March 3, 2017

Financial news for PTCT dated on 2017-03-03: Barclays Downgrades PTC Therapeutics to Equal-Weight, Lowers Price Target to \$13.00

Financial news for PTCT dated on 2017-03-02: Mid-Afternoon Market Update: Crude Oil Down 2%; Ameresco Shares Spike Higher

Financial news for PTCT dated on 2017-03-02: 20 Biggest Mid-Day Losers For Thursday

Financial news for PTCT dated on 2017-03-02: PTC Therapeutics Sharply Lower After ACT CF Trial Misses Primary, Secondary Endpoints

Financial news for PTCT dated on 2017-03-02: Mid-Morning Market Update: Markets Edge Lower; Abercrombie & Fitch Earnings Miss Views

Financial news for PTCT dated on 2017-03-02: PTC Therapeutics Shares Resume, Now Down 27%

Financial news for PTCT dated on 2017-03-02: PTC Therapeutics to Resume at 8:30 AM ET

Financial news for PTCT dated on 2017-03-02: PTC Therapeutics Shares to Resume Trade

at 8:30 a.m. EST

Financial news for PTCT dated on 2017-03-02: UPDATE: PTC Plans To Discontinue Curent Clinical Development of ataluren In CF Close Ongoing Extension Studies And Withdraw Marketing Application Authorization In Europe

Financial news for PTCT dated on 2017-03-02: PTC Therapeutics ACT CF Trial Missed Primary And Secondary Endpoints

Financial news for PTCT dated on 2017-03-02: PTC Therapeutics Halted News Pending

Financial news for PTCT dated on 2017-02-16: Credit Suisse Says PTC Therapeutics Could Trade Up Between \$80 And \$100

Financial news for PTCT dated on 2017-02-16: Credit Suisse In Note Says They Think PTC Therapeutics Could Trade Up To \$80-\$100/Share Believes It Has A Compelling Risk/Reward Setup Coming Into CF Data

Financial news for PTCT dated on 2017-01-18: Watch These 8 Huge Call Purchases In Wednesday Trade

Financial news for PTCT dated on 2017-01-17: Option Alert: PTC Therapeutics Mar 18.0 Calls Sweep: 853 @ ASK \$2.091: 883 traded vs 99 OI: Earnings 2/28 After Close (est) \$14.70 Ref

Financial news for PTCT dated on 2017-01-09: PTC Therapeutics Sees FY16 Cash Of \$230M, FY17 Cash Of ~\$160M

Financial news for PTCT dated on 2017-01-06: PTC Therapeutics Granted Orphan Drug Designation for RG7916 for Treatment of Spinal Muscular Atrophy

Financial news for PTCT dated on 2017-01-05: PTC Therapeutics Reports Initiation of FIREFISH Study in Infant SMA Patients

Financial news for PTCT dated on 2016-12-15: PTC Therapeutics Sells off to Low of \$11.99 on Volume

Financial news for PTCT dated on 2016-11-14: 18 Biggest Mid-Day Gainers For Monday

Financial news for PTCT dated on 2016-11-14: Credit Suisse Upgrade Keeps The Rally Going In PTC Therapeutics

Financial news for PTCT dated on 2016-11-14: 7 Biggest Price Target Changes For Monday

Financial news for PTCT dated on 2016-11-14: The Market In 5 Minutes: A Couple Of Pharma Stocks Move 70% In Opposite Directions

Financial news for PTCT dated on 2016-11-14: Benzinga's Top Upgrades

Financial news for PTCT dated on 2016-11-14: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for PTCT dated on 2016-11-14: PTC Therapeutics+ 14.87% Premarket @\$12.98; Credit Suisse Upgrades to Outperform, Raises PT to \$25.00

Financial news for PTCT dated on 2016-11-14: Credit Suisse Upgrades PTC Therapeutics, Inc. - Common Stock to Outperform, Raises to \$25.00

Financial news for PTCT dated on 2016-11-11: Mid-Afternoon Market Update: Gold Futures Down 3.5%; PTC Therapeutics Shares Spike Higher

Financial news for PTCT dated on 2016-11-11: 12 Biggest Mid-Day Gainers For Friday

Financial news for PTCT dated on 2016-11-11: Mid-Day Market Update: Crude Oil Down Over 3%; NVIDIA Shares Jump On Earnings Beat

Financial news for PTCT dated on 2016-11-11: A Timeline Of PTC Therapeutics' Translarna Journey

Financial news for PTCT dated on 2016-11-11: Technical Alert - PTC Therapeutics Inc. Sharply Higher EMA Decision

Financial news for PTCT dated on 2016-11-11: Benzinga's Volume Movers

Financial news for PTCT dated on 2016-11-11: Mid-Morning Market Update: Markets Mostly Lower; J C Penney Q3 Sales Miss Estimates

Financial news for PTCT dated on 2016-11-11: Citigroup Upgrades PTC Therapeutics,

Inc. - Common Stock to Buy, Raises to \$15.00

Financial news for PTCT dated on 2016-11-11: Sarepta +5.7% Premarket Following EMA Renewal of Marketing Authorization for PTC's Translarna

Financial news for PTCT dated on 2016-11-11: PTC Therapeutics Surges 88% On European Marketing Authorization

Financial news for PTCT dated on 2016-11-11: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for PTCT dated on 2016-11-11: Adam Feuerstein @adamfeuerstein Tweet: EMA's flexibility w/ \$PTCT Ataluren has to be positive for \$SRPT Exondys, right? Logically consistent?

Financial news for PTCT dated on 2016-11-11: PTC Therapeutics Spikes to High of \$10.99 Premarket; CHMP Recommended Renewal of Translarna's Marketing Authorization for Nonsense Mutation DMD

Financial news for PTCT dated on 2016-11-11: PTC Therapeutics, Inc. Reports CHMP Recommends Renewal of Translarna's Marketing Authorization for Nonsense Mutation Duchenne Muscular Dystrophy Based on Continued Positive Benefit-Risk Assessment

Financial news for PTCT dated on 2016-11-03: 20 Biggest Mid-Day Losers For Thursday

Financial news for PTCT dated on 2016-11-02: PTC Therapeutics Reports Q3 EPS \$(1.03) vs. Est. \$(1.22), Rev. \$22.98M vs. Est. \$19.7M

Financial news for PTCT dated on 2016-10-21: 16 Stocks Moving In Friday's Pre-Market Session

Financial news for PTCT dated on 2016-10-20: PTC Therapeutics Says 'Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients'

Financial news for PTCT dated on 2016-10-20: PTC Therapeutics Reports Spinal Muscular Atrophy Program via RG7916 Advances into Phase 2 Studies in SMA Patients

Financial news for PTCT dated on 2016-10-18: Technical Alert: PTC Therapeutics Continues Lower

Financial news for PTCT dated on 2016-10-17: Mid-Afternoon Market Update: Dow Falls Over 50 Points; RLJ Entertainment Shares Spike Higher

Financial news for PTCT dated on 2016-10-17: 12 Biggest Mid-Day Losers For Monday

Financial news for PTCT dated on 2016-10-17: Mid-Day Market Update: Hasbro Gains On Earnings Beat; PTC Therapeutics Shares Slide

Financial news for PTCT dated on 2016-10-17: PTC Therapeutics Down 30% Off FDA Denial Letter

Financial news for PTCT dated on 2016-10-17: Mid-Morning Market Update: Markets Edge Lower; Bank of America Profit Tops Views

Financial news for PTCT dated on 2016-10-17: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for PTCT dated on 2016-10-17: UPDATE: PTC Therapeutics Says Intends to Escalate Appeal to Next Supervisory Level of FDA

Financial news for PTCT dated on 2016-10-17: PTC Therapeutics Reports Regulatory Update on Translarna for Nonsense Mutation DMD: FDA's ODE-I Denied Co. First Appeal of Refuse of File Letter Issued by DNP on Feb. 22, '16

Financial news for PTCT dated on 2016-10-06: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for PTCT dated on 2016-10-04: Option Alert: PTCT Oct16 14.0 Calls Sweep: 500 @ ASK \$1.10: 515 traded vs 863 OI: Earnings 11/14 \$13.53 Ref

Financial news for PTCT dated on 2016-09-30: 15 Biggest Mid-Day Gainers For Friday

Financial news for PTCT dated on 2016-09-29: Camber Capital Management Reports 5.84% Passive Stake in PTC Therapeutics in 13G

Financial news for PTCT dated on 2016-09-22: 3 Reasons Sarepta Shares Rallied Following News Of \$225 Million Offering

Financial news for PTCT dated on 2016-09-20: Jefferies Examines The Effect Of

Sarepta's Drug Approval On PTC Therapeutics

Financial news for PTCT dated on 2016-09-19: Technical Alert: PTC Therapeutics Moves In Sympathy With Sarepta Therapeutics

Financial news for PTCT dated on 2016-09-19: 15 Biggest Mid-Day Gainers For Monday

Financial news for PTCT dated on 2016-09-19: PTC Therapeutics Gets Big Boost From Sarepta's DMD Drug Approval

Financial news for PTCT dated on 2016-09-19: Sarepta Shares Now Up 95% to ~\$55; PTC Therapeutics Shares Up 27% as Traders Viewing Accelerated Approval Filing by FDA on Sarepta's Eteplirsen as Sympathy Event for PTCT

Financial news for PTCT dated on 2016-09-14: PTC Therapeutics Spikes to High of \$9.29 on Volume

Financial news for PTCT dated on 2016-09-14: The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A

Financial news for PTCT dated on 2016-09-14: Can You Guess This Chart?

Financial news for PTCT dated on 2016-08-25: PTC Therapeutics Spikes to High of \$8.47 on Volume; Traders Circulating Report of NICE Recommendation

Financial news for PTCT dated on 2016-08-05: Mid-Afternoon Market Update: Dow Up 160 Points; Lantheus Shares Surge On Earnings Beat

Financial news for PTCT dated on 2016-08-05: 25 Biggest Mid-Day Gainers For Friday

Financial news for PTCT dated on 2016-08-04: PTC Therapeutics Reports Q2 \$(1.14) vs. Est. \$(1.27), Rev. \$15.633M vs. Est. \$14.6M

Financial news for PTCT dated on 2016-08-01: Benzinga's Top Initiations

Financial news for PTCT dated on 2016-07-26: 15 Biggest Mid-Day Losers For Tuesday

Financial news for PTCT dated on 2016-07-26: 8 Biggest Price Target Changes For Tuesday

Financial news for PTCT dated on 2016-07-26: Need For New Drug Trial Increases Long-Term Risk For PTC Therapeutics, Says Wedbush

Financial news for PTCT dated on 2016-07-26: Credit Suisse Downgrades PTC Therapeutics to Neutral, Lowers PT to \$6.00

Financial news for PTCT dated on 2016-07-25: UPDATE: PTC Therapeutics Initiated Pediatric Clinical Study of Translarna for Treatment of nnDMD in Patients 2-5 in Age

Financial news for PTCT dated on 2016-07-25: UPDATE: PTC Therapeutics Says Renewal Assessment Prodedure with CHMP 'cannot be completed by mid-year 2016'

Financial news for PTCT dated on 2016-07-25: PTC Therapeutics Offers Regulatory Update on Translarna

Financial news for PTCT dated on 2016-07-20: NICE publishes final guidance recommending ataluren for children with Duchenne muscular dystrophy

Financial news for PTCT dated on 2016-07-07: 12 Stocks Moving In Thursday's Pre-Market Session

Financial news for PTCT dated on 2016-06-24: Adam Feuerstein @adamfeuerstein Tweet: No decision on \$PTCT Translarna out of EMA CHMP today.

Financial news for PTCT dated on 2016-05-25: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PTCT dated on 2016-05-05: PTC Therapeutics Reports Q1 EPS \$(1.22) Vs Est \$(1.26), Sales \$18.878M Vs Est \$13.74M

Financial news for PTCT dated on 2016-04-27: PTC Therapeutics Says Canceled DB Conference Appearance on March 29 Due to Investor Call on May 5

Financial news for PTCT dated on 2016-04-27: Hearing PTC Therapeutics Cancelled Out of DB Conference

Financial news for PTCT dated on 2016-04-26: PTC Therapeutics Names Dr. Tuyen Ong as Chief Medical Officer

Financial news for PTCT dated on 2016-04-18: Why NICE Recommendation Is Turning Point For PTC Therapeutics Shares

Financial news for PTCT dated on 2016-04-18: PTC Therapeutics Investors Taking Profits Monday Following ~42% Rally on Friday, Stock Down ~5%; Downside Comes Amid Earlier Positive Comments from Oppenheimer

Financial news for PTCT dated on 2016-04-18: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for PTCT dated on 2016-04-15: Mid-Afternoon Market Update: Infosys Rises Following Q4 Results; Ixia Shares Slide

Financial news for PTCT dated on 2016-04-15: PTC Therapeutics Spikes 40% After Translarna Update In England

Financial news for PTCT dated on 2016-04-15: Shares of PTC Therapeutics Resume Trade, Now Up 19.9%

Financial news for PTCT dated on 2016-04-15: PTC Therapeutics Shares to Resume Trade 11:22:30

Financial news for PTCT dated on 2016-04-15: PTC Shares Halted on Circuit Breaker, Now Up 14%

Financial news for PTCT dated on 2016-04-15: PTC Therapeutics Announces NICE Recommends Translarna For Patient Treatment Of Nonsense Mutation DMD In England

Financial news for PTCT dated on 2016-03-23: Why These 5 Stocks Are Moving After Hours

Financial news for PTCT dated on 2016-03-23: PTC Therapeutics Reports Workforce Reduction By 18%, Will Incur \$2.5M Charge

Financial news for PTCT dated on 2016-03-14: PTC Therapeutics Offers Update on Health Canada Review of Translarna for Treatment of DMD

Financial news for PTCT dated on 2016-03-14: PTC Therapeutics To Withdraw Current NDS From Health Caanada To Resubmit With ACT DMD Results; Expects Review In 1H 2016

Financial news for PTCT dated on 2016-03-14: PTC Therapeutics Reports Presentation of Results from Phase 3 ACT DMD Clinical Trial of Translarna in Patients with Duchenne Muscular Dystrophy at 5th International Congress of Myology

Financial news for PTCT dated on 2016-03-02: 11 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PTCT dated on 2016-03-02: PTC Therapeutics Announces Inducement Grants for Non-Statutory Stock Options to Buy 29.5K Shares of Common Stock to 12 New Employees

Financial news for PTCT dated on 2016-03-01: Mid-Afternoon Market Update: American Public Education Rises Following Q4 Results; PTC Therapeutics Shares Fall

Financial news for PTCT dated on 2016-03-01: Wall Street Really Blew It On PTC Therapeutics

Financial news for PTCT dated on 2016-03-01: Stocks Hitting 52-Week Lows

Financial news for PTCT dated on 2016-03-01: PTC Therapeutics: Oppenheimer Bull Cuts Target From \$111 To \$39; Jefferies Less Certain on Translarna

Financial news for PTCT dated on 2016-03-01: Jefferies Maintains Hold on PTC Therapeutics, Lowers PT to \$8.00

Financial news for PTCT dated on 2016-03-01: Wedbush Downgrades PTC Therapeutics to Neutral

Financial news for PTCT dated on 2016-03-01: Cowen & Company Downgrades PTC Therapeutics to Market Perform

Financial news for PTCT dated on 2016-03-01: Credit Suisse Maintains Outperform on PTC Therapeutics, Lowers PT to \$12.00

Financial news for PTCT dated on 2016-03-01: Barclays Maintains Overweight on PTC Therapeutics, Lowers PT to \$40.00

Financial news for PTCT dated on 2016-02-29: 7 Stocks Moving In Today's After-Hours Session

Financial news for PTCT dated on 2016-02-29: PTC Therapeutics Says RTF Letter Received from FDA Related to Translarna for nmDMD, Translarna EU Regulatory Submissions for DMD, CF Under Review by CHMP

Financial news for PTCT dated on 2016-02-29: PTC Therapeutics Sees FY16 Sales Ex-US Translarna nmDMD \$65M-\$85M vs \$94.9M Est.

Financial news for PTCT dated on 2016-02-29: PTC Therapeutics Reports Q4 EPS \$(1.50) vs \$(1.25) Est., Sales \$12.734M vs \$13.2M Est.

Financial news for PTCT dated on 2016-02-29: What You May Be Missing About PTC Therapeutics In Germany

Financial news for PTCT dated on 2016-02-29: Bank of America Downgrades PTC Therapeutics to Neutral

Financial news for PTCT dated on 2016-02-29: Cowen Suspends PTC Therapeutics Target, Puts Rating Under Review

Financial news for PTCT dated on 2016-02-29: Earnings Scheduled For February 29, 2016

Financial news for PTCT dated on 2016-02-27: UPDATE: Cowen & Co Reviewing Recommendation On PTCT Citing Need For Clarity On Translarna's US/EU Value

Financial news for PTCT dated on 2016-02-27: Cowen & Co Places Outperform Rating 'Under Review' For PTC Therapeutics, Removes \$120 PT

Financial news for PTCT dated on 2016-02-26: PTC Therapeutics Confirms Early Reports

Financial news for PTCT dated on 2016-02-26: Adam Feuerstein @adamfeuerstein Tweet: BREAKING \$PTCT: German reimbursement arbitration panel cuts price of DMD drug ataluren by 65%. (Decision Feb. 25) pic.twitter.com/dPyMdza7U5

Financial news for PTCT dated on 2016-02-25: Benzinga's M&A Chatter for Thursday February 25, 2016

Financial news for PTCT dated on 2016-02-25: PTC Therapeutics Mounts Tepid Comeback

Financial news for PTCT dated on 2016-02-25: Sanofi Spokesperson on Word of PTC Therapeutics Interest Tells Benzinga Co. 'Does Not Comment on Market Rumors'

Financial news for PTCT dated on 2016-02-25: EXCLUSIVE: Sanofi In Talks To Buy PTC Therapeutics

Financial news for PTCT dated on 2016-02-25: Street Insider Reports Sanofi Could Bid for PTC Therapeutics

Financial news for PTCT dated on 2016-02-25: PTC Therapeutics Spikes to High of \$12.26 on Volume

Financial news for PTCT dated on 2016-02-25: Shares of PTC Therapeutics Spike Higher

Financial news for PTCT dated on 2016-02-25: Oppenheimer Sees 'Significant Upside Potential' In PTC Therapeutics

Financial news for PTCT dated on 2016-02-25: Oppenheimer Reiterates Outperform on PTC Therapeutics, Lowers PT to \$111.00

Financial news for PTCT dated on 2016-02-24: Benzinga's Top Upgrades

Financial news for PTCT dated on 2016-02-24: Benzinga's Top Downgrades

Financial news for PTCT dated on 2016-02-24: Jefferies Upgrades PTC Therapeutics To Hold; Sees FDA Approvability Priced In And Is Uncertain On EU Decision

Financial news for PTCT dated on 2016-02-24: Citi Downgrades PTC Therapeutics Following Major Setback

Financial news for PTCT dated on 2016-02-24: Citigroup Downgrades PTC Therapeutics to Neutral

Financial news for PTCT dated on 2016-02-24: RBC Capital Downgrades PTC Therapeutics to Sector Perform, Lowers PT to \$11.00

Financial news for PTCT dated on 2016-02-24: Jefferies Upgrades PTC Therapeutics to Hold

Financial news for PTCT dated on 2016-02-23: Mid-Afternoon Market Update: Fitbit

Drops On Weak Forecast; MRC Global Shares Surge

Financial news for PTCT dated on 2016-02-23: PTC Therapeutics Down 56% After Receipt Of Refuse To File Letter For Translama

Financial news for PTCT dated on 2016-02-23: Mid-Day Market Update: Crude Oil Down 4.5%; Newport Shares Spike Higher

Financial news for PTCT dated on 2016-02-23: JP Morgan Downgrades PTC Therapeutics to Neutral, Lowers PT to \$22.00, Removed From Focus List

Financial news for PTCT dated on 2016-02-23: Mid-Morning Market Update: Markets Open Lower; Home Depot Beats Q4 Estimates

Financial news for PTCT dated on 2016-02-23: Stocks Hitting 52-Week Lows

Financial news for PTCT dated on 2016-02-23: PTC Therapeutics Shares Fall 29% Premarket to \$20 Following Announcement of Receipt of Refuse to File Letter from FDA for Translarna

Financial news for PTCT dated on 2016-02-23: Shares Of PTC Therapeutics Fall From 28.26 To \$20.05, Down 29% After Refusal To File Letter From FDA For Translarna

Financial news for PTCT dated on 2016-02-23: PTC Receives Refuse to File Letter from FDA for Translarna, Application Was Not Complete To Permit A Substantive Review

Financial news for PTCT dated on 2016-02-11: Option Alert: PTCT Sep16 34.0 Calls Sweep: 576 @ ASK \$5.50: 576 traded vs 1 OI: Earnings 2/26 \$24.12 Ref

Financial news for PTCT dated on 2016-01-21: The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug

Financial news for PTCT dated on 2016-01-20: Credit Suisse Bullish On Most Big Pharma Names

Financial news for PTCT dated on 2016-01-19: Credit Suisse Initiates Coverage on PTC Therapeutics at Outperform, Announces \$36.00 PT

Financial news for PTCT dated on 2015-12-22: Option Alert: PTCT Jan16 30.0 Puts Sweep: 517 @ ASK \$2.95: 548 traded vs 2870 OI: \$32.18 Ref

Financial news for PTCT dated on 2015-12-16: Oppenheimer Sees European Regulator Agenda Signaling Comming Decision On Adoption Of PTC Therapeutics Translama Drug

Financial news for PTCT dated on 2015-11-25: Morning Market Losers

Financial news for PTCT dated on 2015-11-25: Benzinga's Top Downgrades

Financial news for PTCT dated on 2015-11-25: Benzinga's Top #PreMarket Losers

Financial news for PTCT dated on 2015-11-25: Jefferies Downgrades PTC Therapeutics to Underperform, Lowers PT to \$18.00

Financial news for PTCT dated on 2015-11-19: PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna(tm) for Patients with Cystic Fibrosis

Financial news for PTCT dated on 2015-11-09: PTC Therapeutics Reports Q3 EPS (\$1.27) Vs Est (\$1.15), Sales \$9.78M Vs Est \$9.88M

Financial news for PTCT dated on 2015-10-23: Benzinga's Top Initiations

Financial news for PTCT dated on 2015-10-23: Jefferies Initiates Coverage on PTC Therapeutics at Hold, Announces \$26.00 PT

Financial news for PTCT dated on 2015-10-19: Here's Why Biotechs Fell On Monday

Financial news for PTCT dated on 2015-10-16: Roth Capital On PTC Therapeutics: 'Staying On The Sidelines' Until Regulatory Clarity

Financial news for PTCT dated on 2015-10-16: Option Alert: \$PTCT Dec \$20 Put Sweep; 3875 Contracts Above Ask @\$1.79

Financial news for PTCT dated on 2015-10-16: Martin Shkreli @MartinShkreli Tweet: shorting \$PTCT. sometimes these things take time to "work" and you have to "pick your spots".

Financial news for PTCT dated on 2015-10-16: Morning Market Gainers

Financial news for PTCT dated on 2015-10-16: Oppenheimer Sees Translarna Approval

'Likely,' Believes PTC Is 'Catalyst Rich' Through 1H'16

Financial news for PTCT dated on 2015-10-16: Benzinga's Top #PreMarket Gainers

Financial news for PTCT dated on 2015-10-16: Barclays Thinks PTC Therapeutics Has 234% Upside

Financial news for PTCT dated on 2015-10-15: Barclays Remains Overweight PTC Shares With Price Target Of \$100/Share, Potential Upside Of 234%

Financial news for PTCT dated on 2015-10-15: Barclays Says, "we are encouraged by the data and would be buyers of PTC shares. "

Financial news for PTCT dated on 2015-10-15: PTC Therapeutics Erasing Loses After Phase 3 Translarna Data Released, Touched Low of \$19/Share After Hours; Now Trading At \$30.57/Share

Financial news for PTCT dated on 2015-10-15: PTC Therapeutics Shares Resume, Trading Down ~21%

Financial news for PTCT dated on 2015-10-15: Martin Shkreli @MartinShkreli Tweet: This \$PTCT trial was a "redo" of another failed trial and failed again. This drug has no efficacy whatsoever and an implausible/refuted MOA.

Financial news for PTCT dated on 2015-10-15: UPDATE: PTC Phase 3 Trial Results Showed Translarna Was Not Statistically Significant in The Overall Intent-To-Treat Study Population

Financial news for PTCT dated on 2015-10-15: UPDATE: PTC Therapeutics Says Primary Endpoint of Change from Baseline In 6-Minute Walk Test Demonstrated a 15 Meter Benefit And Wasn't Statistically Significant

Financial news for PTCT dated on 2015-10-15: UPDATE: Primary Endpoint For PTC Phase 3 ACT DMD Clinical Trial Strong Safety Profile Of Translarna Confirmed

Financial news for PTCT dated on 2015-10-15: Shares of PTC Therapeutics to Resume Trade at 4:35 p.m. EDT

Financial news for PTCT dated on 2015-10-15: Sarepta Spikes Higher After-Hours on PTC News

Financial news for PTCT dated on 2015-10-15: UPDATE: PTC Says Data Shows Translarna's Ability to Slow Disease Progression, Pre-Specified Meta-Analysis of Combo Showed Benefit Across Primary, Key Secondary Efficacy Endpoints

Financial news for PTCT dated on 2015-10-15: PTC Therapeutics Reports Will Close Rolling NDA Submission for Translarna to FDA by End of '15

Financial news for PTCT dated on 2015-10-15: PTC Therapeutics Halted-News Pending

Financial news for PTCT dated on 2015-10-05: PTC Therapeutics Could Quintuple In Price, Oppenheimer Predicts

Financial news for PTCT dated on 2015-10-04: PTC Therapeutics Phase 2 Data from Spinal Muscular Atrophy Program to be Presented at 20th International Annual Congress of WMS

Financial news for PTCT dated on 2015-09-30: PTC Therapeutics Submits European Application For Translarna for Cystic Fibrosis

Financial news for PTCT dated on 2015-09-18: Health Canada Initiates Review of PTC Therapeutics New Drug Submission for Translarna for Treatment of DMD

Financial news for PTCT dated on 2015-09-04: PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award

Financial news for PTCT dated on 2015-08-25: Citi Starts PTC Therapeutics At Buy, Sees One Of Year's Biggest Binary Events Coming

Financial news for PTCT dated on 2015-08-25: Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cempra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics

Financial news for PTCT dated on 2015-08-19: Treating Female Sexual Dysfunction (And How To Invest In It)

Financial news for PTCT dated on 2015-07-17: Option Alert: PTC Therapeutics Aug \$80 Call Sweep; 1000 Contracts above Ask @\$0.63; Now \$58.71

Financial news for PTCT dated on 2015-07-15: Mid-Day Market Update: Receptos Jumps After Merger News; Marten Transport Shares Slide

Financial news for PTCT dated on 2015-07-15: Mid-Morning Market Update: Markets Mostly Higher; Bank Of America Tops Q2 Views

Financial news for PTCT dated on 2015-07-15: Morning Market Gainers

Financial news for PTCT dated on 2015-07-15: Benzinga's Top Upgrades

Financial news for PTCT dated on 2015-07-15: JP Morgan Upgrades PTC Therapeutics to Overweight

Financial news for PTCT dated on 2015-07-02: Seeing Cautious Note on PTC Therapeutics

Financial news for PTCT dated on 2015-06-23: Watch These 10 After-Hours Movers Today

Financial news for PTCT dated on 2015-06-02: Hearing Deal Reporter Says Roche Looking at PTC Therapeutics

Financial news for PTCT dated on 2015-05-21: PTC Therapeutics: Quantifiable Added Benefit for First Approved Therapy for Nonsense Mutation Duchenne Muscular Dystrophy

Financial news for PTCT dated on 2015-05-06: Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks

Financial news for PTCT dated on 2015-05-05: Credit Suisse Assumes PTC Therapeutics at Outperform, Announces \$100.00 PT, Rated 'Top Idea'

Financial news for PTCT dated on 2015-05-05: Benzinga's Top Downgrades

Financial news for PTCT dated on 2015-05-05: Roth Capital Downgrades PTC Therapeutics To Neutral

Financial news for PTCT dated on 2015-05-05: Roth Capital Downgrades PTC Therapeutics to Neutral, Lowers PT to \$63.00

Financial news for PTCT dated on 2015-04-28: PTC Therapeutics' Cancer Stem Cell Program Targeting BMI1 Enters Phase 1

Financial news for PTCT dated on 2015-04-27: Did The AAN Meeting Affect Biogen, PTC Therapeutics, GW Pharma Or Isis Pharma?

Financial news for PTCT dated on 2015-04-20: CAR-T Therapy Stocks Hit Hard Following AACR Data

Financial news for PTCT dated on 2015-04-20: Phase 1 Data from Spinal Muscular Atrophy Program to be Presented at the 2015 American Academy of Neurology Annual Meeting

Financial news for PTCT dated on 2015-04-17: It's A Big Weekend For Biotech

Financial news for PTCT dated on 2015-04-16: Cowen Says PTC Therapeutics Is A Buy

Financial news for PTCT dated on 2015-04-16: Cowen & Company Upgrades PTC Therapeutics to Outperform

Financial news for PTCT dated on 2015-04-10: Is This Stock A Vertex Pharma Clone?

Financial news for PTCT dated on 2015-03-24: PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company -Adam F/Street.com

Financial news for PTCT dated on 2015-03-05: Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst

Financial news for PTCT dated on 2015-03-04: Barclays Expands Coverage To 7 New Biotech Stocks

Financial news for PTCT dated on 2015-03-04: Barclays Initiates Coverage on PTC Therapeutics at Overweight, Announces \$100.00 PT

Financial news for PTCT dated on 2015-03-02: JP Morgan Downgrades PTC Therapeutics to Neutral

Financial news for PTCT dated on 2015-02-27: PTC Therapeutics Reports Q4 EPS -\$0.84 vs Est -\$0.86, Sales \$12.7M Vs Est \$8.00M

Financial news for PTCT dated on 2015-02-27: Earnings Scheduled For February 27, 2015

Financial news for PTCT dated on 2015-02-25: Adam Feuerstein @adamfeuerstein Tweet: \$PTCT for Sale? Only to a Foolish, Risk-Blind Buyer thestreet.com/story/13058217... via @TheStreet

Financial news for PTCT dated on 2015-02-25: Adam Feuerstein @adamfeuerstein Tweet: The math used by Credit Suisse to raise its \$PTCT price target to \$100 from \$66 assumes 100% probability of success for Ataluren DMD ph3.

Financial news for PTCT dated on 2015-02-24: UPDATE: Hearing Now that Vertex is Not Interested in PTC Therapeutics, They are Interested in a Cystic Fibrosis Play, PTC is Not a Major Cystic Fibrosis Play

Financial news for PTCT dated on 2015-02-24: Hearing Unconfirmed Market Chatter of Vertex Interest in PTC Therapeutics

Financial news for PTCT dated on 2015-02-24: Benzinga's Volume Movers

Financial news for PTCT dated on 2015-02-23: Benzinga's M&A Chatter for Monday February 23, 2015

Financial news for PTCT dated on 2015-02-23: Update: Biomarin, Shire Potential Buyers for PTC Therapeutics, According to Sources -Reuters

Financial news for PTCT dated on 2015-02-23: Adam Feuerstein @adamfeuerstein Tweet: \$BMRN is interested in buying \$PTCT? That's hard to believe.

Financial news for PTCT dated on 2015-02-23: PTC Therapeutics Shares Rise 22% on Report of Potential Sale

Financial news for PTCT dated on 2015-02-23: PTC Therapeutics Exploring Sale, According to Sources -Reuters

Financial news for PTCT dated on 2015-01-22: Deutsche Bank Loves These Small-Cap Biotech Stocks

Financial news for PTCT dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Financial news for PTCT dated on 2015-01-11: Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2015

Financial news for PTCT dated on 2014-12-23: PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy

Financial news for PTCT dated on 2014-12-19: PTC Therapeutics' Translarna Granted Orphan Drug Designation In U.S. and Europe

Financial news for PTCT dated on 2014-12-17: PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635

Financial news for PTCT dated on 2014-12-09: Shares of PTC Therapeutics Up Nearly 10% Over Last Hour as Hearing Traders Discussing DealReporter Alert Suggesting Shire or Sanofi Could Be Potential Suitors

Financial news for PTCT dated on 2014-12-04: Martin Shkreli Tweet: @MartinShkreli shorting \$PTCT

Financial news for PTCT dated on 2014-12-04: Shares of PTC Therapeutics Moving Lower on December 3 Article from UK's Chronicle Live Website on Translarna

Financial news for PTCT dated on 2014-12-03: PTC Therapeutics Announces Launch Of Translarna In Germany

Financial news for PTCT dated on 2014-11-19: Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial In Patients With SMA

Financial news for PTCT dated on 2014-11-17: PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Financial news for PTCT dated on 2014-10-27: Translarna Phase 2b Data Published In Muscle & Nerve

Financial news for PTCT dated on 2014-10-13: UPDATE: Bank Of America Reiterates On PTC Therapeutics On Positive Outlook

Financial news for PTCT dated on 2014-10-13: Bank of America Maintains Buy on PTC Therapeutics, Lowers PT to \$48.00

Financial news for PTCT dated on 2014-10-09: PTC Therapeutics Prices 3M Share

Offering @\$36.25/Share

Financial news for PTCT dated on 2014-10-09: PTC Therapeutics Prices Offering of 3M Shares at \$36.25/Share

Financial news for PTCT dated on 2014-10-08: PTC Therapeutics Reports 3M Share Offering

Financial news for PTCT dated on 2014-10-01: PTC Therapeutics Presenting Now at Leering Rare Disease Roundtable

Financial news for PTCT dated on 2014-09-25: Benzinga's Volume Movers

Financial news for PTCT dated on 2014-09-24: PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Financial news for PTCT dated on 2014-09-15: Midday Gainers From September 15 - RadioShack Corporation, Rewalk Robotics Ltd And More

Financial news for PTCT dated on 2014-09-15: Stocks Hitting 52-Week Highs

Financial news for PTCT dated on 2014-09-15: Benzinga's Top Initiations

Financial news for PTCT dated on 2014-09-15: Deutsche Bank Initiates PTC Therapeutics At Buy

Financial news for PTCT dated on 2014-09-15: Deutsche Bank Initiates Coverage on PTC Therapeutics at Buy, Announces \$75.00 PT

Financial news for PTCT dated on 2014-08-07: PTC Therapeutics Reports Q2 EPS of \$(0.86) vs \$(0.75) Est; Revenue of \$1.42M vs \$1.71M Est

Financial news for PTCT dated on 2014-08-04: PTC Therapeutics Announce Conditional Approval in EU For Translarna

Financial news for PTCT dated on 2014-08-04: PTC Therapeutics Reports Conditional Approval in EU for Translarna

Financial news for PTCT dated on 2014-07-18: Biotech Enters Reporting Season With Large Caps Central To Sector Performance

Financial news for PTCT dated on 2014-07-07: Roth Capital Initiates Coverage on PTC Therapeutics at Buy, Announces \$34.00 PT

Financial news for PTCT dated on 2014-06-30: PTC Therapeutics Initiates Confirmatory Phase 3 Clinical Trial of Translarna(tm) (ataluren) in Patients With Nonsense Mutation Cystic Fibrosis (nmCF)

Financial news for PTCT dated on 2014-05-23: Market Wrap For May 23: Markets Marginally Higher; S&P 500 Closes Above 1,900

Financial news for PTCT dated on 2014-05-23: #Premarket Prep Technical Update - PTC Therapeutics Trading Sharply Higher

Financial news for PTCT dated on 2014-05-23: Benzinga's Volume Movers

Financial news for PTCT dated on 2014-05-23: Morning Market Movers Friday, May 23, 2014

Financial news for PTCT dated on 2014-05-23: PTC Shares More Than Double Following CHMP's Positive Opinion On Translarna(TM)

Financial news for PTCT dated on 2014-05-23: Benzinga's Top #PreMarket Gainers

Financial news for PTCT dated on 2014-05-23: Shares of PTC Rally Nearly 150% as Co. Gives Updates, Received Positive Opinion from CHMP on Translarna(TM)

Financial news for PTCT dated on 2014-05-23: PTC Therapeutics Gives EMA Update

Financial news for PTCT dated on 2014-05-16: Ataluren Phase 3 Trial Results in Nonsense Mutation Cystic Fibrosis Published in The Lancet Respiratory Medicine

Financial news for PTCT dated on 2014-03-06: PTC Therapeutics Reports Q4 EPS of \$(0.75) vs \$(0.57) Est; Revenue of \$4.41M vs \$6.15M Est

Financial news for PTCT dated on 2014-02-19: PTC Therapeutics Closes Registered Offering, Reports Net Proceeds ~\$118M

Financial news for PTCT dated on 2014-02-12: PTC Therapeutics Prices 4.489M Share

Offering at \$24.50/Share

Financial news for PTCT dated on 2014-02-12: PTC Therapeutics Raises Secondary Offering from \$75M to \$100M

Financial news for PTCT dated on 2014-01-24: Benzinga's Top #PreMarket Losers

Financial news for PTCT dated on 2014-01-22: PTC Therapeutic, Roche Announce Joint Program in Spinal Muscular Atrophy Enters First Stage of Clinical Development

Financial news for PTCT dated on 2013-12-26: The Five Best Performing Stocks of 2013

Financial news for PTCT dated on 2013-12-12: PTC Therapeutics Reports Ataluren Clinical Data Demonstrate an Increase in Dystrophin Expression in nmDMD Patients

Financial news for PTCT dated on 2013-09-30: PTC Therapeutics To Join Russell 2000 Index

Financial news for PTCT dated on 2013-07-26: Cowen & Company Initiates Coverage on PTC Therapeutics at Outperform, Announces \$33.00 PT

Financial news for PTCT dated on 2013-07-17: UPDATE: Wedbush Initiates PTC Therapeutics at Outperform on Ataluren Potential

Financial news for PTCT dated on 2013-07-17: Benzinga's Top Initiations

Financial news for PTCT dated on 2013-07-17: Wedbush Initiates Coverage on PTC Therapeutics at Outperform, Announces \$55.00 PT

Financial news for PTCT dated on 2013-07-16: Traders in PTC Therapeutics Attributing Recent Spike Higher to New Outperform Rating, \$55 Target at Wedbush

Financial news for PTCT dated on 2013-07-15: UPDATE: Credit Suisse Initiates PTC Therapeutics at Outperform on Bullish Thesis

Financial news for PTCT dated on 2013-07-15: UPDATE: J.P. Morgan Initiates PTC Therapeutics at Overweight on Ataluren Potential

Financial news for PTCT dated on 2013-07-15: Benzinga's Top Initiations

Financial news for PTCT dated on 2013-07-15: Credit Suisse Initiates Coverage on PTC Therapeutics at Outperform, Announces \$24.00 PT

Financial news for PTCT dated on 2013-07-15: JP Morgan Initiates Coverage on PTC Therapeutics at Overweight, Announces \$20.00 PT

Financial news for PTCT dated on 2013-06-20: PTC Therapeutics Opens at \$15.80/Share, Priced at \$15

Financial news for PTCT dated on 2013-06-20: Shares of PTC Therapeutics Now Open for Quote, IPO Expected to Open at 10:40AM EDT

Financial news for PTCT dated on 2013-06-20: PTC Therapeutics Prices 8.372M Share IPO at \$15.00/Share

Financial news for PTCT dated on 2013-06-13: PTC Therapeutics Sees IPO of 6.9M Shares in \$13-16/Share Range